← The Wire
REGNNasdaq
REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · NY · CIK 872589
Regeneron Pharmaceuticals discovers, develops, and commercializes medicines for serious diseases
⚡ Elevated coverage
$64.18B
Market cap
$631.81
Last close
-0.2%
1D
+3.1%
5D
734K
Volume
Price · last 39 sessions-10.9%
May 4L $600.66 · H $723.41Jun 29
165
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 17, 20268-KResults of OperationsApr 29, 20268-KResults of OperationsApr 8, 20268-KResults of OperationsJan 30, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KResults of OperationsOct 28, 20258-KResults of OperationsOct 6, 20258-KResults of OperationsAug 1, 20258-KShareholder VoteJun 18, 20258-KResults of OperationsApr 29, 20258-KResults of Operations · Company UpdateFeb 4, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KResults of OperationsOct 31, 20248-KResults of OperationsOct 7, 20248-KResults of OperationsAug 1, 20248-KResults of OperationsJul 8, 20248-KShareholder VoteJun 20, 20248-KResults of OperationsMay 2, 20248-KResults of OperationsFeb 2, 20248-KExecutive ChangeJan 31, 20248-KResults of Operations · Reg FD DisclosureJan 8, 20248-KResults of OperationsNov 2, 20238-KResults of OperationsOct 5, 20238-KExecutive ChangeSep 8, 20238-KResults of OperationsAug 3, 20238-KBylaw Amendment · Shareholder VoteJun 14, 20238-KResults of OperationsMay 4, 20238-KExecutive ChangeApr 17, 20238-KResults of OperationsApr 10, 20238-KMaterial Agreement · New Debt / ObligationMar 29, 20238-KResults of OperationsFeb 3, 20238-KResults of Operations · Reg FD DisclosureJan 9, 20238-KMaterial Agreement · Agreement TerminatedDec 20, 20228-KResults of OperationsNov 3, 20228-KExecutive ChangeOct 3, 20228-KResults of OperationsAug 3, 20228-KShareholder VoteJun 15, 20228-KMaterial AgreementJun 2, 20228-KResults of OperationsMay 4, 20228-KMaterial Agreement · New Debt / ObligationMar 8, 20228-KResults of OperationsFeb 4, 20228-KResults of Operations · Reg FD DisclosureJan 10, 20228-KResults of OperationsNov 4, 20218-KMaterial AgreementSep 16, 20218-KResults of OperationsAug 5, 20218-KShareholder VoteJun 16, 20218-KResults of OperationsMay 6, 20218-KResults of OperationsFeb 5, 20218-KMaterial AgreementJan 15, 20218-KResults of Operations · Reg FD DisclosureJan 11, 20218-KExecutive ChangeJan 5, 20218-KResults of OperationsNov 5, 20208-KMaterial AgreementAug 19, 20208-KMaterial Agreement · New Debt / ObligationAug 12, 20208-KResults of OperationsAug 5, 20208-KMaterial Agreement · Reg FD DisclosureJul 7, 20208-KExecutive Change · Shareholder VoteJun 16, 20208-KMaterial Agreement · Reg FD DisclosureMay 29, 20208-KResults of OperationsMay 5, 20208-KMaterial AgreementApr 7, 20208-KResults of OperationsFeb 6, 20208-KResults of Operations · Reg FD DisclosureJan 13, 20208-KResults of OperationsNov 5, 20198-KResults of OperationsAug 6, 20198-KShareholder VoteJun 19, 20198-KResults of OperationsMay 7, 20198-KMaterial Agreement · New Debt / ObligationMay 3, 20198-KMaterial AgreementApr 10, 20198-KResults of OperationsFeb 6, 20198-KMaterial Agreement · Results of OperationsJan 7, 20198-KMaterial Agreement · Agreement TerminatedDec 17, 20188-KResults of OperationsNov 6, 20188-KReg FD Disclosure · Company UpdateOct 12, 20188-KResults of OperationsAug 2, 20188-KShareholder VoteJun 13, 20188-KResults of OperationsMay 3, 20188-KResults of OperationsFeb 8, 20188-KExecutive ChangeJan 18, 20188-KMaterial Agreement · Results of OperationsJan 8, 20188-KExecutive ChangeJan 2, 2018
Insider Activity
In the 90 days to Mar 2, 2026: 4 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $789.28 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $788.96 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 11 | $785.48 | $9K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 10 | $783.62 | $8K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 9 | $784.48 | $7K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $786.61 | $6K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $777.46 | $5K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 5 | $779.69 | $4K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 3 | $780.69 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $787.34 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $782.62 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $781.21 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $778.30 | $2K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 331 | $780.45 | $258K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 298 | $782.10 | $233K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 220 | $783.29 | $172K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 209 | $781.28 | $163K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 208 | $779.55 | $162K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 160 | $784.45 | $126K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 56 | $785.61 | $44K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 5 reputable articles · skews – neutral.
MarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day12d agoMarketWatchRegeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market18d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors21d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains24d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains25d agoMarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance